CNR Institutional Research Information System

SANTORO, MASSIMO

SANTORO, MASSIMO  

Istituto di Endocrinologia e Oncologia Sperimentale ''G. Salvatore'' - IEOS  

Mostra records
Risultati 1 - 20 di 132 (tempo di esecuzione: 0.055 secondi).
Titolo Data di pubblicazione Autore(i) File
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer 1-gen-2017 De Falco V.; Carlomagno F.; Li H.Y.; Santoro M.
A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. 1-gen-2016 Cantisani, Mc; Parascandolo, A; Perälä, M; Allocca, C; Fey, V; Sahlberg, N; Merolla, F; Basolo, F; Laukkanen, Mo; Kallioniemi, Op; Santoro, M; Castellone, Md
Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma 1-gen-2015 Castellone M.D.; Laukkanen M.O.; Teramoto H.; Bellelli R.; Ali G.; Fontanini G.; Santoro M.; Gutkind J.S.
Genetics: The genomic landscape of papillary thyroid carcinoma 1-gen-2015 Santoro, Massimo; Melillo Rosa, M
Identification of novel small molecule inhibitors of oncogenic RET kinase 1-gen-2015 Moccia, M; Liu, Q; Guida, T; Federico, G; Brescia, A; Zhao, Z; Choi, Hg; Deng, X; Tan, L; Wang, J; Billaud, M; Gray, Ns; Carlomagno, F; Santoro, M
Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. 1-gen-2015 Visciano, C; Liotti, F; Prevete, N; Cali', G; Franco, R; Collina, F; de Paulis, A; Marone, G; Santoro, M; Melillo, Rm
Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies 1-gen-2014 Bossi D.; Carlomagno F.; Pallavicini I.; Pruneri G.; Trubia M.; Raviele P.R.; Marinelli A.; Anaganti S.; Cox M.C.; Viale G.; Santoro M.; Di Fiore P.P.; Minucci S.
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation 1-gen-2014 Frett, B; Moccia, M; Carlomagno, F; Santoro, M; Li, Hy
Indoleamine 2,3-Dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment 1-gen-2014 Moretti S.; Menicali E.; Voce P.; Morelli S.; Cantarelli S.; Sponziello M.; Colella R.; Fallarino F.; Orabona C.; Alunno A.; De Biase D.; Bini V.; Mameli M.G.; Filetti S.; Gerli R.; Macchiarulo A.; Melillo R.M.; Tallini G.; Santoro M.; Puccetti P.; Avenia N.; Puxeddu E.
Attacking cancer with molecularly targeted agents Editorial overview 1-gen-2013 Santoro, M; Carlomagno, F
Central role of RET in thyroid cancer 1-gen-2013 Santoro M.; Carlomagno F.
Oncogenic rearrangements driving ionizing radiation-associated human cancer 1-gen-2013 Santoro M.; Carlomagno F.
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. 1-gen-2013 De Falco, V; Buonocore, P; Muthu, M; Torregrossa, L; Basolo, F; Billaud, M; Gozgit, Jm; Carlomagno, F; Santoro, M
Tumour Suppressor Role of the CL2/DRO1/CCDC80 Gene in Thyroid Carcinogenesis. 1-gen-2013 Ferraro A; Schepis F; Leone V; Federico A; Borbone E; Pallante P; Berlingieri MT; Chiappetta G; Monaco M; Palmieri D; Chiariotti L; Santoro M; Fusco A.
A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. 1-gen-2012 Faraonio, R; Salerno, P; Passaro, F; Sedia, C; Iaccio, A; Bellelli, R; Nappi, Tc; Comegna, M; Romano, S; Salvatore, G; Santoro, M; Cimino, F
Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. 1-gen-2012 Tamburrino A; Molinolo AA; Salerno P; Chernock RD; Raffeld M; Xi L; Gutkind JS; Moley JF; Wells SA Jr; Santoro M.
CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells. 1-gen-2012 De Falco V; Tamburrino A; Ventre S; Castellone MD; Malek M; Manié SN; Santoro M.
CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. 1-gen-2012 Ward Y; Lake R; Martin PL; Killian K; Salerno P; Wang T; Meltzer P; Merino M; Cheng SY; Santoro M; GarciaRostan G; Kelly K.
CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. 1-gen-2012 Torregrossa, L; Giannini, R; Borrelli, N; Sensi, E; Melillo, Rm; Leocata, P; Materazzi, G; Miccoli, P; Santoro, M; Basolo, F
FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. 1-gen-2012 Bellelli, R; Castellone, Md; Garciarostan, G; Ugolini, C; Nucera, C; Sadow, Pm; Nappi, Tc; Salerno, P; Cantisani, Mc; Basolo, F; Gago, Ta; Salvatore, G; Santoro, M